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next	 generation	 sequencing	 we	 detected	 mutations	 of	 SETD2	 in	 an	 additional	 3.8%	 of	 patients	
(23/602).	 In	most	 cases,	SETD2-deletions	or	mutations	were	often	observed	as	a	 clonal	 event	and	
always	 as	 a	 mono-allelic	 lesion,	 leading	 to	 reduced	 mRNA	 expression	 in	 SETD2-disrupted	 cases.	
Patients	with	SETD2	 abnormalities	 and	wild-type	TP53	 and	ATM	 from	 five	 clinical	 trials	 employing	
chemotherapy	 or	 chemo-immunotherapy,	 had	 reduced	 progression-free	 and	 overall	 survival	








proteins,	 catalyzed	 by	 histone	 methyltransferases	 (HMTs),	 is	 an	 important	 regulator	 of	 gene	




cell	 renal	cell	 carcinoma	 (ccRCC)2	and	subsequently	 in	other	solid	 tumors	e.g.	high	grade	gliomas.3	
Moreover,	 SETD2	mutations	 have	 been	 reported	 in	 a	 subset	 of	 patients	with	 acute	 lymphoblastic	
leukemia4	 and	acute	myeloid	 leukemia,	 especially	 those	with	 rearrangements	 in	 the	another	HMT	
gene,	MLL.5	 SETD2	 is	 the	 only	 enzyme	 that	 catalyzes	 the	 trimethylation	 of	 lysine	 36	 on	 histone	 3	
(H3K36me3),	one	of	the	major	chromatin	marks	associated	with	active	transcription.	Recent	studies	
have	 linked	 SETD2	 to	 the	maintenance	of	 genomic	 integrity,	 through	 coordination	of	 homologous	
recombination	repair	after	double	strand	breaks.	The	loss	of	SETD2	impairs	DNA	repair	and	enhances	
genomic	instability,	supporting	its	tumor	suppressor	role.	6-9		




genomic	 copy-number	 aberrations	 (CNAs)	 like	 del(13q),	 del(11q),	 trisomy	 12	 and	 del(17p)	 and	
recurrent		driver	mutations	in	genes	such	as	TP53,	ATM,	SF3B1	and	NOTCH1,	respectively	(reviewed	
in	10).	Mutations	frequently	involve	genes	encoding	proteins	with	important	roles	in	cell	signalling,	cell	
cycle	 control,	 DNA	 repair	 and	 RNA-splicing	 and	 processing;	 however	 the	 reported	 incidence	 of	
mutations	in	chromatin	modifiers	is	lower	than	in	many	other	haematological	malignancies.		
In	this	study,	we	report	the	identification	of	recurrent	deletions	and	mutations	of	the	SETD2	gene	in	
large,	 well-characterized	 CLL	 cohorts.	 SETD2	 lesions	 appear	 to	 represent	 early	 events	 in	 CLL	








Four	 randomized	 trials	 (ADMIRE,	 ARCTIC,	 UK	 CLL4	 11,	 GCSG	 CLL8	 12)	 compared	 chemo	 or	 chemo-







[n=110]);	 details	 of	 the	 cohort	 composition	 and	 SETD2	 analysis	 are	 summarised	 in	 Table	 1,	
Supplementary	methods	and	Supplementary	figure	1.	DNA	was	extracted	from	CLL	B	cell	samples	(all	
with	>80%	tumour	purity)	and	from	matched	germ-line	DNA	for	SETD2-mutated	cases	as	outlined	in	





Affymetrix	 SNP6.0	platform,	aligned	onto	 the	human	genome	sequence	 (GRCh37)	and	analysed	 in	
Partek	 Genomics	 Suite	 (Partek	 Inc,	Missouri,	 USA)	 as	 reported	 previously.14-18	 DNA	 from	 201	 pre-
treatment	extension	cases	(ADMIRE	and	ARCTIC)	was	hybridized	to	the	Illumina	HumanOmni1-Quad	





Haloplex	 Target	 Enrichment	 system	 (Agilent	 Technologies)	 (Supplementary	Methods	 Table	 1)	 and	
















and	 reversed	 transcribed	 using	 the	 Improm™II	 RT-PCR	 kit	 (Promega,	 UK)	 according	 to	 the	
manufacturer’s	 instruction.	Primers	and	probes	for	the	housekeeping	genes	(18s)	and	target	genes	



























(≥3	 deletions25,	 p=0.04)(Figure	 1B).	 GISTIC	 2.0	 analysis	 26,	 an	 algorithm	 for	 identifying	 statistically	
significant	regions	of	CNA	above	an	estimated	background	rate	(FDR	q-value	<0.25),	showed	that	in	
39	TP53	 deleted	 cases	 (del(3p),	 n=15),	 the	 SETD2	 region	 on	 3p21.31,	was	 deleted	 at	 a	 significant	
frequency	(q-value=0.001),	ranked	third	after	del(13q)	and	del(17p)	(Figure	S2).		
Interestingly,	 SETD2	 deletions	 without	 concomitant	 TP53/ATM	 abnormalities	 [n=6]	 also	 exhibited	
significantly	more	genomic	complexity	than	wildtype	patients	(p=0.01.	Figure	1D).	Two	SETD2-deleted	










In	order	 to	study	 the	clonal	nature	of	 the	SETD2	deletions,	we	assigned	each	genomic	CNA	with	a	
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DNA	 from	 three	 patients	 and	 confirmed	 that	 the	 mutations	 were	 somatically	 acquired	 (p.D99G,	
p.W1306*,	p.E1955Q)	(Figure	S5A).	
To	 corroborate	 this	 preliminary	 observation,	 we	 investigated	 231	 cases	 of	 our	 pre-treatment	








p.VLEYC1576del,	p.V1190M.	None	of	 these	SETD2	mutations	 (Table	2)	are	annotated	 in	COSMIC29.	
During	the	preparation	of	this	manuscript,	a	study	performed	by	Puente	et	al.	in	506	CLL	patients	also	
described	 both	 SETD2	 mutations	 (0.8%	 of	 cases)	 and	 deletions	 in	 3p	 (2%	 of	 cases)	 whose	 MDR	
encompassed	SETD2	30	whilst	Landau	et	al	identified	SETD2	mutations	in	8/538	(1.5%)	cases	23.	











and	 SNP6.0	 copy	 number	 data	 available,	 by	 employing	 the	 ABSOLUTE	 algorithm.31	 This	 approach	
estimates	the	cancer	cell	fraction	(CCF)	harboring	a	given	mutation	by	correcting	for	sample	purity	and	
local	 copy	 number	 changes.	 Mutations	 were	 classified	 as	 clonal	 if	 the	 CCF	 was	 >0.95	 with	 a	
probability	>0.5,	and	sub-clonal	otherwise.32	In	additional	cases	with	proven-somatic	SETD2	mutations	
(n=4)	and	paired	copy	number	data	 from	our	pre-treatment	validation	cohorts,	we	performed	this	




























epigenetic	histone	mark	 to	other	 important	 cellular	processes	 such	as	 the	 regulation	of	mismatch	
repair,	 efficient	 homologous	 recombination	 and	 the	 maintenance	 of	 genomic	 stability.7-9	 In	 vitro	
inhibition	of	Setd2	decreases	global	levels	of	H3K36me3	and	impairs	the	recruitment	of	the	mismatch	
recognition	protein	hMutSα	onto	chromatin,	thereby	preventing	appropriate	DNA	mismatch	repair.	
Cells	 lacking	 the	 Setd2	 protein	 display	 microsatellite	 instability	 and	 have	 elevated	 levels	 of	
spontaneous	 mutations.7,36-38	 Inactivating	 SETD2	 mutations	 were	 first	 described	 in	 ccRCC2,6,	
subsequently	in	other	solid	tumors	such	as	paediatric	high-grade	gliomas	and	most	recently	in	a	subset	
of	 patients	 with	 acute	 lymphoid	 and	 myeloid	 leukemias.	 2,5,39,40	 SETD2	 mutations	 in	 ccRCC	 are	
frequently	associated	with	3p	deletions	resulting	in	loss	of	both	SETD2	and	VHL	genes,	while	in	acute	
leukemias,	SETD2	mutations	may	be	bi-allelic	but	3p	 loss	 is	rare.	SETD2	genomic	abnormalities	are	
associated	 with	 decreased	 H3K36me3	 levels,	 a	 distinctive	 DNA	 methylation	 signature6	 and	





CLL8	 cohort	 in	 which	 3p	 deletions	 had	 also	 been	 detected	 18,	 to	 confirm	 the	 incidence	 of	 SETD2	
disruption	and	evaluate	its	biological	and	clinical	consequences	in	CLL.	Previously	untreated	patients	
sampled	at	 randomization	 to	chemo	or	chemo-immunotherapy	 trials	had	a	similar	 incidence	of	3p	
deletions	(4.5%)	to	that	seen	in	the	discovery	cohort	while	a	higher	incidence	of	loss	(9%)	was	found	
in	the	ultra-high	risk	cohort.	The	inclusion	of	additional	cohorts	enabled	a	smaller	MDR	to	be	defined,	














sub-types	 (including	 del(17p)	 cases).	 Furthermore,	 SETD2	 mRNA	 expression	 was	 not	 found	 to	 be	
correlated	with	methylation	 status.	 Together,	 this	 suggests	 that	DNA	methylation	does	 not	 play	 a	
substantial	role	in	regulating	SETD2	expression	in	B-CLL	cells,	as	previously	noted	in	acute	leukemia.	
In	addition,	when	we	analysed	SETD2	expression	in	CLL	studies	deposited	in	the	Oncomine	database,43	























association	 with	 TP53	 abnormalities	 hinder	 an	 accurate	 assessment	 of	 its	 clinical	 consequences.	






In	 summary,	 our	 current	 study	 provides	 the	 first	 comprehensive	 analysis	 of	 CNAs	 and	mutations	
targeting	 the	 SETD2	 gene	 in	 a	 large	 cohort	 of	 patients	 with	 CLL.	 We	 find	 somatic	 deletions	 and	
mutations	in	~7%	of	CLL	patients	requiring	treatment.	These	associate	with	TP53	dysfunction,	genomic	
complexity	and	chromothripsis	and	may	be	early	clonal	events.	Functional	studies	are	now	warranted	
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Wild%type vs.- TP53&ab. P<0.001
SETD2&ab.&vs.- TP53&ab.&P=0.114
Wild%type-vs.- SETD2&ab.-P<0.001








































































































69	 c.5863G>C	 p.E1955Q	 P;D	 yes	 rs761536283	 -	 P	 M.Musculus	
100	 c.296A>G	 p.D99G	 -;D	 yes	 -	 -	 M	 M.Musculus	
255	 c.4633C>A	 p.Q1545K	 P;T	 ND	 -	 -	 M	 D.Melano	




















149	 c.2008G>A	 p.E670K	 P;D	 yes	 rs374976472	 -	 M	 G.Gallus	
88	 c.5224A>C	 p.M1742L	 P;D	 yes	 -	 - M	 D.Rerio	
4273	 c.148G>A	 p.A50T	 D;D	 ND	 rs191985301	 0.020%	(1/5008)	 P	 M.Musculus	
4530	 c.6885A>G	 p.I2295M	 B;D	 ND	 rs150476239	 0.020%	(1/5008)	 M	 D.Melano	
4546	 c.500C>T	 p.P167L	 B;-	 ND	 rs78682369	 0.020%	(1/5008)	 P	
not	
conserved	
4715	 c.5666T>C	 p.M1889T	 P;D	 ND	 rs148097513	 0.040%	(2/5008)	 M	 G.Gallus	
4172	 c.5666T>C	 p.M1889T	 P;D	 ND	 rs148097513	 0.040%	(2/5008)	 M	 G.Gallus	
4426	 c.1604A>G	 p.N535S	 B;T	 ND	 -	 -	 P	 M.Musculus	
4426	 c.265C>T	 p.L89F	 B,D	 ND	 -	 -	 P	 M.Musculus	
#266	 c.5755-5781delGAAGAGGAAGAATTGCAGTCACAAC	 p.EEEELQSQQ1919fs	 -;-	 yes	 -	 -	 M	 M.Musculus	
#278	 c.5411_5412delAC	 p.L1804fs	 -;-	 yes	 -	 -	 M	 partly	conserved	
#269	 c.4727_4741delTCCTAGAATATTGTG	 p.VLEYC1576del	 -;-	 yes	 -	 -	 M	 M.Musculus	
















#028	 c.6433G>T	 p.G2145*	 -;D	 yes	 -	 -	 M	 M.Musculus	
#065	 c.4973C>G	 p.S1658*	 -;T	 yes	 -	 -	 M	 M.Musculus	
*15	 c.2225C>G	 p.S742*	 -;T	 yes	 -	 -	 M	 partly	conserved	
*#141	 c.6985C>T	 p.Q2329*	 -;T	 yes	 -	 -	 M	 not	conserved	
*#141	 c.7616A>T	 p.K2539I	 D;D	 yes	 -	 -	 M	 M.Musculus	
*177	 c.3876-3877delGT	 p.Y1293fs	 -;-	 yes	 -	 -	 M	 M.Musculus	
Footnote:	ND:	Not	done,	due	to	lack	of	germline	material.	PolyPhen2	prediction	(B	=	Benign;	P	=	Probably	Damaging;	D	=	Damaging;	-	=	No	prediction).	SIFT	prediction	(D	=	Damaging;	T	=	Tolerated;	-	=	No	prediction).	
MAF	(minimal	allele	frequency	in	1000	Genomes	project).	MutationTaster2	prediction	(P=polymorphism;	M=disease	causing).	Underlined	text	indicates	an	AID/APOBEC	recognition	motif.	Mutation	annotation	was	
performed	against	COSMIC	v	73	and	no	overlapping	mutations	were	found.	*Cases	included	in	Puente	et	al	and	#	Landau	et	al.	
